U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H21N3O
Molecular Weight 259.3467
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRIMAQUINE

SMILES

COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1

InChI

InChIKey=INDBQLZJXZLFIT-UHFFFAOYSA-N
InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3

HIDE SMILES / InChI
Bulaquine (also known as Elubaquine) is a primaquine pro-drug and an anti-malarial agent, which was developed by Central Drug Research Institute, Lucknow. The drug is marketed under the name Aablaquin in combination with chloroquine and is prescribed for the treatment and prevention of p. vivax. The exact mechanism of action of bulaquine remains unknown.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.5 µM [IC50]
68.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AABLAQUIN

Approved Use

Treatment and prevention of p. vivax.

Launch Date

9.4668482E11
Curative
PRIMAQUINE

Approved Use

Primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria.

Launch Date

-5.661792E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
53 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
104 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
66 ng/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
65 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.5 μg × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1 μg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
443 ng × h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
468 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.9 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.4 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.3 h
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.4 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Other AEs: Malaise, Headache...
Other AEs:
Malaise (1 patient)
Headache (2 patients)
Nausea (1 patient)
Pyrexia (1 patient)
Vomiting (1 patient)
Dizziness (1 patient)
Asthenia (1 patient)
Pruritus (1 patient)
Haemoglobin decreased (1 patient)
Dyspepsia (1 patient)
Sources:
0.6 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.6 mg/kg, 1 times / day
Co-administed with::
(artesunate)
50 mg
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: acute, symptomatic Plasmodium vivax malaria
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Disc. AE: Hematocrit decreased...
AEs leading to
discontinuation/dose reduction:
Hematocrit decreased (4 patients)
Sources:
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Other AEs: Malaise, Headache...
Other AEs:
Malaise (4 patients)
Headache (2 patients)
Nausea (1 patient)
Decreased appetite (3 patients)
Pyrexia (1 patient)
Vomiting (1 patient)
Dizziness (1 patient)
Asthenia (1 patient)
Arthralgia (1 patient)
Muscle spasms (1 patient)
Dyspnoea exertional (1 patient)
Diarrhoea (1 patient)
Sources:
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Other AEs: Malaise, Headache...
Other AEs:
Malaise (3 patients)
Headache (1 patient)
Nausea (2 patients)
Pyrexia (1 patient)
Vomiting (1 patient)
Myalgia (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthenia 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Dizziness 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Dyspepsia 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Haemoglobin decreased 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Malaise 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Nausea 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Pruritus 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Pyrexia 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Vomiting 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Headache 2 patients
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Hematocrit decreased 4 patients
Disc. AE
0.6 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.6 mg/kg, 1 times / day
Co-administed with::
(artesunate)
50 mg
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: acute, symptomatic Plasmodium vivax malaria
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Arthralgia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Asthenia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Diarrhoea 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Dizziness 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Dyspnoea exertional 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Muscle spasms 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Nausea 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Pyrexia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Vomiting 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Headache 2 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Decreased appetite 3 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Malaise 4 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Headache 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Pyrexia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Vomiting 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Myalgia 2 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Nausea 2 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Malaise 3 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Overview

OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

Tox targets
PubMed

PubMed

TitleDatePubMed
Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.
1955 Aug
Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam.
1968 Nov 21
Simultaneous drug reactions in the same patient. Chloroquine-Primaquine sensitivity.
1970 Apr 27
Reaction to primaquine.
1980 Mar
Primaquine induced hemolysis in a Thai soldier.
1989 Dec
Immunogenicity of amodiaquine in the rat.
1990
Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey.
1990 Nov-Dec
In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii.
1994 Jun
[Primaquine and travelers from the Arab world. A report and recommendations].
1995
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
[Hemolysis and primaquine treatment. Preliminary report].
1997
Transcriptional and post-translational regulation of CYP1A1 by primaquine.
2001 Apr
Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline.
2001 May
In vitro cultivation of Chinese strains of Babesia spp.
2002 May
Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics.
2003 Feb
cAMP-dependent exocytosis and vesicle traffic regulate CFTR and fluid transport in rat jejunum in vivo.
2003 Feb
Real-time investigation of the interaction between primaquine phosphate and bovine serum albumin (BSA) by piezoelectric quartz crystal impedance analysis.
2003 Oct 9
Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation.
2004 Feb
Glucose-6-phosphate dehydrogenase deficiency in two returning Operation Iraqi Freedom soldiers who developed hemolytic anemia while receiving primaquine prophylaxis for malaria.
2005 Apr
Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine.
2005 Aug
Exotic diseases of dogs and cats at risk of importation to Ireland.
2005 May 1
Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia.
2006 Nov 14
Drug, dosage, activity, studies of antimalarials by physical methods--II.
2007 May 20
Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate.
2008
Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver.
2008 Dec
Development and validation of UPLC method for determination of primaquine phosphate and its impurities.
2008 Jan 22
[In vitro dissolution profile of primaquine tablets available for malaria treatment in Brazil].
2008 Jan-Feb
Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements.
2008 Jul 1
Formulation and evaluation of primaquine phosphate taste-masked rapidly disintegrating tablet.
2008 Oct
Monkey malaria in a European traveler returning from Malaysia.
2008 Sep
Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.
2009 Nov 15
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Feline babesiosis.
2010 Feb
The Summary Index of Malaria Surveillance (SIMS): a stable index of malaria within India.
2010 Feb 11
Blockade of hERG K(+) channel by antimalarial drug, primaquine.
2010 May
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Novel potent metallocenes against liver stage malaria.
2012 Mar
Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway.
2012 Mar 29
Characterization of Plasmodium liver stage inhibition by halofuginone.
2012 May
Flavones as isosteres of 4(1H)-quinolones: discovery of ligand efficient and dual stage antimalarial lead compounds.
2013 Nov
N-cinnamoylation of antimalarial classics: quinacrine analogues with decreased toxicity and dual-stage activity.
2014 Feb
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.
2015 Feb 19
Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.
2015 Jan 5
Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.
2016 Aug 5
Patents

Sample Use Guides

Primaquine phosphate should be administered concurrently in order to eradicate the exoerythrocytic parasites in a dosage of 1 tablet (equivalent to 15 mg base) daily for 14 days.
Route of Administration: Oral
Inhibition of liver-stage infection by Primaquine (PQ) was determined by measuring the luminescence intensity in Huh-7 cells infected with a firefly luciferase-expressing P. berghei line Huh-7 cells, a human hepatoma cell line, were cultured in 1640 RPMI medium supplemented with 10% v/v fetal bovine serum, 1% v/v nonessential amino acids, 1% v/v penicillin/streptomycin, 1% v/v glutamine, and 10 mM 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7, and maintained at 37 C with 5% CO2. For infection assays, Huh-7 cells (1.0 x 104 per well) were seeded in 96-well plates the day before drug treatment and infection. The medium was replaced by medium containing the appropriate concentration of each compound approximately 1 h prior to infection with sporozoites freshly obtained through disruption of salivary glands of infected female Anopheles stephensi mosquitoes. Sporozoite addition was followed by centrifugation at 1700 g for 5 min. Parasite infection load was measured 48 h after infection by a bioluminescence assay (Biotium). The effect of the compounds on the viability of Huh-7 cells was assessed by the Alamar Blue assay (Invitrogen, U.K.)
Name Type Language
PRIMAQUINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
PRIMAQUINE [VANDF]
Common Name English
PRIMAQUINE [MI]
Common Name English
SN-13272
Code English
(±)-PRIMAQUINE
Common Name English
Primaquine [WHO-DD]
Common Name English
KANAPRIM
Brand Name English
WR-2975
Code English
PRIMACHIN
Common Name English
NEO-QUIPENYL
Brand Name English
MALIRIDE
Brand Name English
NSC-27296
Code English
primaquine [INN]
Common Name English
QUINOLINE, 8-((4-AMINO-1-METHYLBUTYL)AMINO)-6-METHOXY-
Systematic Name English
1,4-PENTANEDIAMINE, N4-(6-METHOXY-8-QUINOLINYL)-
Systematic Name English
Classification Tree Code System Code
LIVERTOX NBK548031
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
WHO-ATC P01BA03
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
NDF-RT N0000175482
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
NCI_THESAURUS C271
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
Code System Code Type Description
EVMPD
SUB10043MIG
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
MESH
D011319
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
FDA UNII
MVR3634GX1
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
PUBCHEM
4908
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
SMS_ID
100000081655
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
ECHA (EC/EINECS)
201-987-2
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL506
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
CAS
90-34-6
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
NSC
27296
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
CHEBI
8405
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID8023509
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
DRUG CENTRAL
2266
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
DAILYMED
MVR3634GX1
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
WIKIPEDIA
Primaquine
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
CAS
57152-47-3
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
SUPERSEDED
NCI_THESAURUS
C62071
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
HSDB
6516
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
MERCK INDEX
M9133
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY Merck Index
LACTMED
Primaquine
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
RXCUI
8687
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB01087
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY
INN
218
Created by admin on Wed Jul 05 23:14:54 UTC 2023 , Edited by admin on Wed Jul 05 23:14:54 UTC 2023
PRIMARY